A Phase 1 Study of S-3304 in Patients With Solid Tumors

Completed · Phase 1

Conditions studied: Solid Tumors

In brief

To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy accessible cancer who have failed previous therapy or to whom no standard therapies are available. To determine the pharmacokinetic profile of S-3304 in this patient population

Key facts

Study ID

NCT00033215

Run by

Shionogi

People needed

32

Starts

2001-11-01

Expected to finish

2003-03-12

Last updated by the study team

2018-04-26

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Biopsy proven diagnosis of solid tumor(s) with biopsy accessible lesion(s)
• Must be able to tolerate oral medication Exclusion criteria
• Patients with other serious illnesses
• Patients who are receiving treatments

Where it is running

• University of Colorado Hospital — Denver, Colorado, United States
• H. Lee Moffitt Concer Center and Research Institute — Tampa, Florida, United States
• Roswell Park Cancer Center — Buffalo, New York, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.